Bruker (BRKR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.49
- Estimate
- $0.38
- Surprise
- +27.5%
- Score at report (before → after)
- 5.4 → 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Bruker (BRKR) beat the $0.38 estimate with diluted EPS of $0.49 — a large 27.5% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.1/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BRKR Sell at 5.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +27.5% surprise compares with a +22.8% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2)
- Weak growth
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $59.41
- Price target
- $60.60
- Stop
- $55.25
- Upside to target
- +2.0%
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
BRKR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $9.05B
- P/E (fwd)
- 24.7
- 52-week range
- $29.84–$65.30
- Off 52-week high
- 9.0%
- RSI (14)
- 55
- Volume vs avg
- 0.63×
- Score today
- 5.1/10